GlassScriptPhysician profile
Khalid A Rao
NPI 1366421273
$488.44
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $161 · 2021: $16.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $86.10 | 2019 | |
| Sunovion Pharmaceuticals INC. | $80.17 | 2019 | |
| Novo Nordisk INC | $77.52 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $53.66 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $41.67 | 2019 | |
| Sanofi-Aventis U.S. LLC | $39.15 | 2019 | |
| Lilly USA, LLC | $36.19 | 2020 | |
| Nestle Healthcare Nutrition INC. | $28.31 | 2020-2021 | |
| Ucb, INC. | $18.14 | 2020 | |
| Scilex Pharmaceuticals INC. | $14.15 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.38 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.